Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports results on March 12 for the period ending December 31 2024
The San Francisco California-based company is expected to report a 25.0% increase in revenue to $29.86 million from $23.89 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nektar Therapeutics is $4.00, above its last closing price of $0.88.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.22 | -0.21 | -0.18 | Beat | 14.6 |
Jun. 30 2024 | -0.21 | -0.20 | -0.25 | Missed | -22.8 |
Mar. 31 2024 | -0.19 | -0.19 | -0.19 | Met | 0 |
Dec. 31 2023 | -0.22 | -0.21 | -0.22 | Missed | -3.6 |
Sep. 30 2023 | -0.21 | -0.20 | -0.24 | Missed | -20.3 |
Jun. 30 2023 | -0.31 | -0.28 | -0.27 | Beat | 4.9 |
Mar. 31 2023 | -0.23 | -0.25 | -0.32 | Missed | -26.7 |
Dec. 31 2022 | -0.44 | -0.45 | -0.32 | Beat | 29.3 |
This summary was machine generated March 10 at 20:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。